Home›Dexlansoprazole›Dexlansoprazole + Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen

Does Dexlansoprazole Interact with Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen?

Dexlansoprazole and Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen have a contraindicated drug interaction according to U.S. FDA drug labeling data. Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole ↓ RPV Coadministration is contraindicated due to potential for loss of virologic response and development of resistance. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Dexlansoprazole Class
Proton Pump Inhibitor
Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen Class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Dexlansoprazole and your doctor is considering prescribing Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Dexlansoprazole(Dexilant)+💊 Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen(Odefsey)

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
Proton Pump Inhibitor
Drug B class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Source
FDA drug label - emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide

What this means in plain English

Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole ↓ RPV Coadministration is contraindicated due to potential for loss of virologic response and development of resistance.

About Dexlansoprazole and Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen

Dexlansoprazole is a Proton Pump Inhibitor, while Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen is a Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor. You may recognize them by the brand names Dexilant and Odefsey. Both medications are taken by mouth. Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Dexlansoprazole and Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.